
Cahill Represents Debt Financing Sources in Multi-Currency Debt Financings, Consisting of \$1.5 Billion Notes Offerings and Approximately \$4.225 Billion Credit Facilities for Jazz Pharmaceuticals

Date: 05/05/21

Cahill represented the initial purchasers in connection with a Rule 144A offering of \$1,500,000,000 aggregate principal amount of 4.375% senior secured notes due 2029 by Jazz Securities Designated Activity Company. Cahill also represented the lead arrangers in connection with a \$3,100,000,000 term B credit facility and a \$500,000,000 revolving credit facility and a €625,000,000 term B credit facility for Jazz Pharmaceuticals Public Limited Company, Jazz Securities Designated Activity Company, Jazz Financing Lux S.a r.l., Jazz Financing I Designated Activity Company, Jazz Pharmaceuticals Ireland Limited, Jazz Financing Holdings Limited, Jazz Pharmaceuticals UK Holdings Limited and Jazz Pharmaceuticals, Inc. Proceeds from the offering and concurrent credit facilities were used to finance Jazz Pharmaceuticals Public Limited Company's acquisition of GW Pharmaceuticals plc, to refinance existing indebtedness, and for other general corporate purposes.

Attorneys

- Elizabeth Yahl
- Stephen G. Harper
- Alexandra L. McIntire